Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis
© Arampatzis et al.; licensee BioMed Central Ltd. 2013
Received: 17 July 2012
Accepted: 1 March 2013
Published: 27 March 2013
Diuretics are among the most commonly prescribed medications and, due to their mechanisms of action, electrolyte disorders are common side effects of their use. In the present work we investigated the associations between diuretics being taken and the prevalence of electrolyte disorders on admission as well as the impact of electrolyte disorders on patient outcome.
In this cross sectional analysis, all patients presenting between 1 January 2010 and 31 December 2011 to the emergency room (ER) of the Inselspital, University Hospital Bern, Switzerland were included. Data on diuretic medication, baseline characteristics and laboratory data including electrolytes and renal function parameters were obtained from all patients. A multivariable logistic regression model was performed to assess the impact of factors on electrolyte disorders and patient outcome.
A total of 8.5% of patients presenting to the ER used one diuretic, 2.5% two, and 0.4% three or four. In all, 4% had hyponatremia on admission and 12% hypernatremia. Hypokalemia was present in 11% and hyperkalemia in 4%. All forms of dysnatremia and dyskalemia were more common in patients taking diuretics. Loop diuretics were an independent risk factor for hypernatremia and hypokalemia, while thiazide diuretics were associated with the presence of hyponatremia and hypokalemia. In the Cox regression model, all forms of dysnatremia and dyskalemia were independent risk factors for in hospital mortality.
Existing diuretic treatment on admission to the ER was associated with an increased prevalence of electrolyte disorders. Diuretic therapy itself and disorders of serum sodium and potassium were risk factors for an adverse outcome.
KeywordsDiuretics Electrolyte disorders Outcome
Diuretics are a mainstay of therapy for a wide variety of diseases ranging from hypertension to the nephrotic syndrome. Despite this key role, the various substances used as diuretics can have serious side effects, such as volume depletion, ototoxicity as with loop diuretics, and, of course, the induction of electrolyte disorders . In an ageing population, the number of patients treated with diuretics for different indications is increasing, as is the relevance of their side effects [2, 3].
Studies investigating diuretic therapy-induced electrolyte disorders have mainly focused on the effects of thiazide diuretics. In a randomized controlled trial in hypertensive patients, serum potassium levels were significantly lower in patients treated with thiazide diuretics . However, only patients who did not receive potassium supplements developed marked hypokalemia with potassium levels below 3.0 mmol/L . A more recent study on hypertensive patients found an incidence of 30% for hyponatremia in patients treated with thiazide diuretics . The same study did not find an increased risk of hospitalization or death in patients with thiazide-induced hyponatremia .
To the best of our knowledge, the prevalence of diuretic use and associated electrolyte disorders have never been investigated in a large group of patients presenting to a hospital emergency room (ER). Findings from large patient series on the impact of non-thiazide diuretics on electrolyte levels are especially lacking.
Therefore, we investigated the associations between diuretics being taken and the prevalence of electrolyte disorders as well as the impact of electrolyte disorders on patient outcome.
All patients admitted to the ER of the Inselspital, University Hospital Bern, in whom serum sodium was measured between 1 January 2009 and 31 December 2010 were included in this cross-sectional analysis. During the study period, 28,523 serum sodium measurements were made in 22,239 patients.
For these 22,239 patients, we gathered data on age, sex, admission type (medical or surgical), country of residence, hospital admission, length of hospital stay, outcome and final diagnosis as classified by the International Classification of Diseases, 10th revision (ICD-10). We also screened the patients’ medications for diuretic use. We gathered information on diuretic use in accordance with the diuretic substances licensed by the Swiss Agency for Therapeutic Products (Swissmedic) as registered in the list of pharmaceutical products (http://www.kompendium.ch). Diuretic agents combined with other substance classes such as antihypertensive agents were also considered in the analysis. We acquired information on the daily dose of the following substances: hydrochlorothiazide, chlorthalidone, butizide, amiloride, spironolactone, eplerenone, furosemide, torasemide, indapamide, metolazone and acetazolamide. Also, if available, the levels of the following analytes were obtained in the patients with serum sodium measurements: potassium, chloride, calcium, phosphate, magnesium, creatinine and urea. Using the values of these variables, the patients were classed as having an electrolyte disorder or not, based on the reference ranges of our central laboratory (sodium: 135 to 145 mmol/L, potassium: 3.5 to 4.7 mmol/L, chloride: 97 to 108 mmol/L, calcium: 2.1 to 2.55 mmol/L, phosphate: 0.84 to 1.45 mmol/L, magnesium: 0.75 to 1.00 mmol/L). We used baseline characteristics and serum creatinine to calculate the estimated glomerular filtration rate in accordance with the Modified Diet in Renal Disease (MDRD) formula.
In the case of multiple admissions, only the first admission to the ER was considered for the analysis.
As this study was a retrospective analysis, there was no need for informed consent. The study was approved by the Ethics Committee of the Canton of Bern, Switzerland.
Data are presented as means ± standard deviation (SD), medians or proportions, as appropriate. Between-group comparisons of continuous variables were performed using the Mann–Whitney U test. Proportions were compared using the χ2 test. When the expected count for cells was lower than five, Fisher’s exact test or the exact test module in SPSS was used.
Multivariable logistic regression analysis was used to explore the association of the various predictors with the presence of electrolyte disorders and with hospitalization. Predefined covariates were added to the logistic regression models.
The cumulative hazard of death was calculated by the Kaplan-Meier method and the log-rank test was used for comparison of groups. Cox regression was used to test associations of the electrolyte disorders with the survival time adjusted for predefined covariates. A two-sided P value of <0.05 was considered statistically significant for all analyses. The statistical analysis was performed using SPSS (SPSS for Windows V.17.0, Chicago, IL, USA).
Baseline laboratory values
Number of patients (%)
Overview of diuretic substances and dosage
Number of patients (%)
Median dose (mg)
The mean serum sodium and serum chloride concentration were significantly lower in patients on diuretic medication on admission to the ER (138 ± 5 vs 139 ± 4 mmol/L, and 101 ± 8 vs 103 ± 6 mmol/L, P <0.0001). The mean serum potassium level was higher in patients on diuretics (4.03 ± 0.63 vs 3.93 ± 0.45 mmol/L, P <0.0001). Patients on diuretics on admission also had a significantly higher mean serum creatinine concentration (116 ± 97 vs 78 ± 56 μmol/L, P <0.0001). Mean MDRD was higher in the group without diuretic medication (58 ± 7 vs 51 ± 14).
In all, 845 patients (4% of patients with sodium measurements) had hyponatremia on admission, 2,630 (12%) hypernatremia, 246 (11%) hypochloremia, and 245 (11%) had hyperchloremia. Hypokalemia was present in 2,459 (11%) and hyperkalemia was found in 974 (4%). Hypophosphatemia was present in 611 (26%) patients, hyperphosphatemia in 215 (9%), hypomagnesemia in 1,308 (24%), and hypermagnesemia in 244 (5%) patients. Hypocalcemia was found in 956 (12%) and hypercalcemia in 108 (1%).
Hyponatremia was more common in patients taking diuretic medication (20% vs 7.7%, P <0.0001). The absolute number of different diuretics taken by patients was associated with a higher prevalence of hyponatremia (P <0.0001). A total of 14% of patients with hyponatremia were taking loop diuretics, 12% thiazide-type diuretics, 6% aldosterone antagonists, and 1% potassium-sparing diuretics. Hyponatremia was more likely to be seen in patients taking loop diuretics (OR 1.23), thiazide diuretics (OR 1.48), potassium-sparing diuretics (OR 1.64) and aldosterone antagonists (OR 2.45) than in patients without diuretics (P <0.0001). In the multivariable regression model, use of thiazide diuretics (odds ratio (OR) 1.44, P <0.0001) and aldosterone antagonists (OR 2.4, P <0.0001) were associated with the presence of hyponatremia after correction for age, sex and estimated glomerular filtration rate (eGFR) as calculated by MDRD.
Hypernatremia was more common in patients taking diuretic medication (2.2% vs 1.6%, P = 0.03). As with hyponatremia, the prevalence of hypernatremia rose with the number of diuretic drugs taken (P = 0.02). Loop diuretics were associated with a significantly higher prevalence of hypernatremia than no diuretic treatment (P = 0.0023). There was no significant difference for all other types of diuretic agent (P >0.05). Use of loop diuretics was an independent risk factor for the presence of hypernatremia after correction for age, sex and eGFR as calculated by MDRD (OR 1.68, P = 0.0232).
Hypokalemia was significantly more common in patients under diuretic therapy (17% vs 11%, P <0.0001). In patients taking loop diuretics (P = 0.0337), thiazide diuretics (P <0.0001) and potassium-sparing diuretics (P <0.0001), hypokalemia was more common than in patients on no diuretic therapy. No difference was seen for aldosterone antagonists (P = 0.7) or carboanhydrase inhibitors (P = 0.9). In the multivariable regression model, loop diuretics (OR 1.27, P = 0.0316), thiazide diuretics (OR 2.18, P <0.0001) and potassium-sparing diuretics (OR 2.13, P = 0.0038) were associated with the presence of hypokalemia. Male sex (OR 0.61, P <0.0001) was also associated with a lower risk for hypokalemia.
Hyperkalemia was significantly more common in patients on diuretic therapy (13% vs 4%, P <0.0001). The prevalence of hyperkalemia was linked to the number of diuretic agents taken by patients (P <0.0001). All types of diuretics were associated with an increased prevalence of hyperkalemia (P <0.05). In the multivariable regression model, potassium-sparing diuretics (OR 3.3, P = 0.0044), aldosterone antagonists (OR 1.76, P <0.0015) and age (OR 1.03, P <0.0001), male sex (OR 1.35, P <0.0001) and serum creatinine (OR 2.23, P <0.0001) were associated with the presence of hyperkalemia (a higher MDRD was protective for the presence of hyperkalemia, OR 0.93, P <0.0001). Thiazide diuretics were associated with a lower risk of hyperkalemia (OR 0.65, P = 0.0054).
In the multivariable regression model, the presence of hyponatremia (OR 1.29, P = 0.0117) and advanced age (OR 1.01, P <0.0001) were associated with a need for hospitalization, while male sex was associated with a lower risk for a need for hospitalization (OR 0.86, P = 0.0186).
Diuretic use and the number of diuretics on admission as well as serum creatinine and age were also associated with increased in-hospital mortality (P <0.0001).
Over a 2-year period, more than 20,000 patients seen in our ER at a large tertiary care hospital for different reasons had serum sodium measurements, which was the prime variable for inclusion in our study. A total of 11% of these patients were taking diuretic agents, and 3% were taking more than one diuretic agent.
Serum sodium levels were significantly lower in patients under diuretic treatment and significantly more patients with hyponatremia were taking a diuretic on admission. Interestingly, potassium levels were significantly higher in patients under diuretic therapy than in those without diuretics. Hypokalemia, however, was significantly more often seen in patients on diuretic agents. Loop diuretics were an independent risk factor for hypernatremia and hypokalemia and thiazide use was associated with the presence of hyponatremia and hypokalemia while they were protective against hyperkalemia. The use of aldosterone antagonists was an independent risk factor for the presence of hyponatremia and hyperkalemia. In a Cox regression model, all forms of dysnatremia and dyskalemia were independent risk factors for in-hospital mortality.
To the best of our knowledge, this is the first study investigating the associations between all types of diuretic and electrolyte levels in a large group of patients presenting to the ER of a major teaching hospital. Our finding of an association between thiazide diuretic and hyponatremia and hypokalemia confirms the results of previous studies [2, 4–7]. The association between hypernatremia and loop diuretic use is explained by the mechanism of action of loop diuretics where the excretion of electrolyte-free water exceeds the increased natriuresis . The mechanism of action of aldosterone antagonists explains their association with hyponatremia and hyperkalemia in the present study .
We found that hyponatremia and hypernatremia on admission are associated with increased mortality and this supports results from previous studies by our group [9–11]. A recent study in patients with myocardial infarction also found increased mortality in patients with hypokalemia and hyperkalemia, supporting our findings on the untoward effects of dyskalemias on outcome .
Although our study cannot demonstrate causality, the effects of electrolyte disorders on different physiological functions suggest an independent effect on mortality [13–17]. This puts the relevance of diuretic therapy-induced electrolyte disorders into a new light: should patients at risk of developing an electrolyte disorder from a certain diuretic be treated with a different substance? This would be an option, since risk profiles exist at least for thiazide-induced hyponatremia [18, 19]. A further option would be to more strongly encourage electrolyte supplementation since this appears to be beneficial . What at least seems crucial is to create awareness in physicians prescribing diuretic therapy that regular electrolyte monitoring should be performed to identify those who may develop the adverse effects of electrolyte disorders, such as an increased risk of falls or fractures [14, 20].
Vasopressin antagonists are the currently newest type of diuretic medication on the market. Today, indications for vasopressin antagonists include euvolemic and hypervolemic hyponatremia . With these new diuretic agents new side effects can be expected: Due to their mechanism of action, namely an inhibition of vasopressin action, overshooting “corrections” of serum sodium could occur. Additionally, hypovolemia and its effects such as dizziness were described in studies on vasopressin antagonists .
One of the limitations of our study is that it was not practicable to obtain data on and evaluate all medications the patients were taking because of the large number of patients included. Information on other substances that may influence serum electrolytes, such as angiotensin-converting enzyme inhibitors, was not available. We also only had information on the patient’s principal diagnosis, thus excluding secondary diagnoses as potential contributory factors, such as cirrhosis of the liver. One of the strengths of the study, however, was the large number of patients included, and we therefore do not expect that these limitations had a substantial effect on our findings.
The spectrum of electrolyte disorders in patients on diuretics admitted to our ER varied with the class of diuretic. All diuretics were associated with an increased prevalence of electrolyte disorders on admission. Diuretic therapy itself and disorders of serum sodium and potassium were risk factors for an adverse outcome.
(estimated) Glomerular filtration rate
International Classification of Diseases, 10th revision
Modified diet in renal disease.
We would like to thank Stephan Fuhrimann and Sabina Utiger from the Department of Emergency Medicine as well as Monika Reusser and Heinz von Allmen from the Center of Laboratory Medicine for their help in acquiring the data. There was no funding source for the realization of this study.
- Rose BD, Post TW: Clinical use of diuretics. Clinical Physiology of Acid–base and Electrolyte Disorders. 2001, New York, NY: McGraw Hill, Volume 15 5Google Scholar
- Mann SJ: The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008, 10: 477-484.View ArticleGoogle Scholar
- Gross P, Palm C: Thiazides: do they kill?. Nephrol Dial Transplant. 2005, 20: 2299-2301.View ArticlePubMedGoogle Scholar
- Siegel D, Hulley SB, Black DM, Cheitlin MD, Sebastian A, Seeley DG, Hearst N, Fine R: Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992, 267: 1083-1089.View ArticlePubMedGoogle Scholar
- Leung AA, Wright A, Pazo V, Karson A, Bates DW: Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011, 124: 1064-1072.View ArticlePubMedGoogle Scholar
- Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP: Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol. 2006, 61: 87-95.View ArticlePubMedPubMed CentralGoogle Scholar
- Shapiro DS, Sonnenblick M, Galperin I, Melkonyan L, Munter G: Severe hyponatraemia in elderly hospitalized patients: prevalence, aetiology and outcome. Intern Med J. 2010, 40: 574-580.View ArticlePubMedGoogle Scholar
- Rose BD: Clinical Physiology of Acid–base and Electrolyte Disorders. 2001, New York, NY: McGraw-Hill, 5Google Scholar
- Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, Metnitz PG: Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 2010, 36: 304-311.View ArticlePubMedGoogle Scholar
- Lindner G, Funk GC, Lassnigg A, Mouhieddine M, Ahmad SA, Schwarz C, Hiesmayr M: Intensive care-acquired hypernatremia after major cardiothoracic surgery is associated with increased mortality. Intensive Care Med. 2010, 36 (2): 304-311.View ArticlePubMedGoogle Scholar
- Lindner G, Funk GC, Schwarz C, Kneidinger N, Kaider A, Schneeweiss B, Kramer L, Druml W: Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis. 2007, 50: 952-957.View ArticlePubMedGoogle Scholar
- Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, Kosiborod M: Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012, 307: 157-164.View ArticlePubMedGoogle Scholar
- Hoorn EJ, Rivadeneira F, van Meurs JB, Ziere G, Stricker BH, Hofman A, Pols HA, Zietse R, Uitterlinden AG, Zillikens MC: Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res. 2011, 26 (8): 1822-1828.View ArticlePubMedGoogle Scholar
- Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA: Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010, 5 (2): 275-280.View ArticlePubMedPubMed CentralGoogle Scholar
- Tolouian R, Alhamad T, Farazmand M, Mulla ZD: The correlation of hip fracture and hyponatremia in the elderly. J Nephrol. 2012, 25 (5): 789-793.View ArticlePubMedGoogle Scholar
- Lenz K, Gossinger H, Laggner A, Druml W, Grimm G, Schneeweiss B: Influence of hypernatremic-hyperosmolar state on hemodynamics of patients with normal and depressed myocardial function. Crit Care Med. 1986, 14: 913-914.PubMedGoogle Scholar
- Halperin ML, Kamel KS: Potassium. Lancet. 1998, 352: 135-140.View ArticlePubMedGoogle Scholar
- Clark BA, Shannon RP, Rosa RM, Epstein FH: Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol. 1994, 5: 1106-1111.PubMedGoogle Scholar
- Chow KM, Szeto CC, Wong TY, Leung CB, Li PK: Risk factors for thiazide-induced hyponatraemia. QJM. 2003, 96: 911-917.View ArticlePubMedGoogle Scholar
- Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006, 119: e71-78.View ArticleGoogle Scholar
- Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008, 371: 1624-1632.View ArticlePubMedGoogle Scholar
- Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006, 355: 2099-2112.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/83/prepub